Vor Biopharma Inc. financial data

Symbol
VOR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
100 Cambridgepark Drive, Suite 101, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.07 K % -30.5%
Debt-to-equity 28.5 % +20.1%
Return On Equity -73.7 % -53.4%
Return On Assets -57.3 % -47.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.2 M shares +2.7%
Common Stock, Shares, Outstanding 68.2 M shares +1.91%
Entity Public Float 136 M USD +17.7%
Common Stock, Value, Issued 7 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 68 M shares +2.66%
Weighted Average Number of Shares Outstanding, Diluted 68 M shares +2.66%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 96.7 M USD +35.9%
General and Administrative Expense 31.2 M USD +4.57%
Operating Income (Loss) -128 M USD -26.6%
Nonoperating Income (Expense) 7.71 M USD +137%
Net Income (Loss) Attributable to Parent -120 M USD -23%
Earnings Per Share, Basic -1.77 USD/shares +17.7%
Earnings Per Share, Diluted -1.77 USD/shares +17.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 45 M USD +5.91%
Marketable Securities, Current 62.5 M USD -62.7%
Other Assets, Current 507 K USD +10.5%
Assets, Current 112 M USD -48.4%
Property, Plant and Equipment, Net 9.17 M USD -22.7%
Operating Lease, Right-of-Use Asset 38.8 M USD -10.9%
Other Assets, Noncurrent 4.82 M USD +72.7%
Assets 167 M USD -39.8%
Accounts Payable, Current 2.33 M USD -27.7%
Employee-related Liabilities, Current 1.91 M USD +21.1%
Accrued Liabilities, Current 6.8 M USD +23.9%
Liabilities, Current 13.2 M USD +5.04%
Operating Lease, Liability, Noncurrent 30.8 M USD -11.4%
Liabilities 44 M USD -7.02%
Accumulated Other Comprehensive Income (Loss), Net of Tax -87 K USD +50%
Retained Earnings (Accumulated Deficit) -371 M USD -48%
Stockholders' Equity Attributable to Parent 123 M USD -46.6%
Liabilities and Equity 167 M USD -39.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.5 M USD -25.5%
Net Cash Provided by (Used in) Financing Activities 96 K USD -96.2%
Net Cash Provided by (Used in) Investing Activities 44 M USD +577%
Common Stock, Shares Authorized 400 M shares 0%
Common Stock, Shares, Issued 68.2 M shares +1.84%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 13.6 M USD
Deferred Tax Assets, Valuation Allowance 104 M USD +52.8%
Deferred Tax Assets, Gross 116 M USD +44.9%
Operating Lease, Liability 34.7 M USD -9.66%
Depreciation 3.6 M USD +22.5%
Payments to Acquire Property, Plant, and Equipment 114 K USD +21.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -120 M USD -24%
Lessee, Operating Lease, Liability, to be Paid 46.8 M USD -11.9%
Property, Plant and Equipment, Gross 18.2 M USD +5.18%
Operating Lease, Liability, Current 3.96 M USD +6.57%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.65 M USD +1.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.59 M USD +4.37%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.1 M USD -21.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.68 M USD +0.56%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.88 M USD +3.01%
Operating Lease, Payments 1.64 M USD +6.15%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 11.7 M USD -0.6%
Share-based Payment Arrangement, Expense 12.4 M USD -4.93%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%